TrialBreast cancer research and treatment2014

A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy.

Anton Buchner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.